Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1711-1711
Open Access | Times Cited: 20

Showing 20 citing articles:

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters
Luca M. Zaeck, Ngoc H. Tan, Wim J. R. Rietdijk, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis
Hagit Kopel, Andre B. Araujo, Alina Bogdanov, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States
Michele Kohli, Michael Maschio, Keya Joshi, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 1532-1545
Open Access | Times Cited: 15
The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan
Kelly Fust, Keya Joshi, Ekkehard Beck, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 434-434
Open Access | Times Cited: 3
Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults
Tianyu Sun, Linwei Li, Katherine E. Mues, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 8, pp. 1771-1787
Open Access | Times Cited: 2
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
Hagit Kopel, Văn Hùng Nguyễn, Alina Bogdanov, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1107-1107
Open Access | Times Cited: 2
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults With Underlying Medical Conditions in the United States
Hagit Kopel, Văn Hùng Nguyễn, Alina Bogdanov, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany
Keya Joshi, Stefan Scholz, Michael Maschio, et al.
Journal of Medical Economics (2023) Vol. 27, Iss. 1, pp. 39-50
Open Access | Times Cited: 4
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4–5 vaccine and practical application of dried blood spots
Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, et al.
Vaccine (2024) Vol. 42, Iss. 22, pp. 126029-126029
Open Access
XBB.1.16‐RBD‐based trimeric protein vaccine can effectively inhibit XBB.1.16‐included XBB subvariant infection
Dandan Peng, Cai He, Zimin Chen, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access
A Response to: A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework’
Ekkehard Beck, Mary T. Bausch-Jurken, Nicolas Van de Velde, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 10, pp. 2195-2202
Open Access
A Letter to the Editor Regarding ‘Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-analysis Using the GRADE Framework’
Hannah R. Volkman, Jennifer L. Nguyen, Luis Jódar, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 10, pp. 2203-2206
Open Access
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults”
Mihaela Georgieva, Tianyu Sun, Ekkehard Beck
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 11, pp. 2457-2459
Open Access
Reply to Volkman et al. Comment on “Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434”
Michele Kohli, Keya Joshi, Ekkehard Beck, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1175-1175
Open Access
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
Amy Lee, Benjamin Davido, Ekkehard Beck, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity
Milja Belik, Arttu Reinholm, Pekka Kolehmainen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States
Hagit Kopel, Andre B. Araujo, Alina Bogdanov, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 12
Open Access
Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines
Leire Fernández-Ciriza, José Luís del Pozo, Nazaret Betanzos, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1408-1408
Open Access
The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review
Roberto Debbag, D Rudin, Francesca Ceddia, et al.
Infectious Diseases and Therapy (2024)
Open Access
Page 1

Scroll to top